Rayaldee
Payments companies reported to CMS as associated with Rayaldee. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rayaldee, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rayaldee
These are the largest totals companies reported as associated with Rayaldee. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Varshasb Broumand | San Antonio, TX | Nephrology (Internal Medicine) | $25,748.53 |
| Harry Dounis | Neptune, NJ | Nephrology (Internal Medicine) | $19,558.17 |
| Juan Lerma | Evergreen Park, IL | Nephrology (Internal Medicine) | $9,015.76 |
| Matt Rosenberg | Jackson, MI | Family Medicine | $9,000.00 |
| James Wetmore | Minneapolis, MN | Nephrology (Internal Medicine) | $7,054.35 |
| Alexander Swan | Brooklyn, NY | Nephrology (Internal Medicine) | $4,491.50 |
| Stuart Sprague | Evanston, IL | Nephrology (Internal Medicine) | $2,419.86 |
| Mark Molitch | Chicago, IL | Endocrinology, Diabetes & Metabolism | $1,000.00 |
| Carl Dukes | San Antonio, TX | Nephrology (Internal Medicine) | $997.73 |
| Gina Inthavong | Shreveport, LA | Nurse Practitioner | $980.62 |
Prescribed Rayaldee?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.